Related Experiment Videos
Evaluation of a combined measles-mumps-rubella-chickenpox vaccine
Developments in Biological Standardization
|January 1, 1986
Insights
A combined measles, mumps, rubella (MMR) and chickenpox vaccine showed no difference in harmless side-reactions or sero-conversion rates compared to single vaccines in young children.
Area of Science:
- Pediatric Vaccinology
- Immunology
Background:
- The MMR vaccine protects against measles, mumps, and rubella.
- Chickenpox is a common childhood viral infection.
- Combined vaccines offer convenience but require safety and efficacy evaluation.
Purpose of the Study:
- To compare the safety and immunogenicity of a combined MMR + Chickenpox vaccine with individual component vaccines.
- To assess side-reaction profiles and sero-conversion rates in young children.
Main Methods:
- Groups of 15- to 24-month-old children were vaccinated.
- One group received single component vaccines.
- Another group received a high-potency combined MMR + Chickenpox vaccine.
Main Results:
- No significant difference was observed in the low percentage of harmless side-reactions between vaccine groups.
- Sero-conversion rates were high (95-100%) in both groups, indicating comparable immune response.
Conclusions:
- The combined MMR + Chickenpox vaccine is as safe and immunogenic as individual vaccines in children aged 15-24 months.
- Combined vaccination strategies can be effectively implemented without compromising safety or efficacy.
Abstract:
There was neither a difference in the (low) percentage of only harmless side-reactions nor in the rate of sero-conversions (between 95-100%), when groups of 15 to 24 months old children were vaccinated either with the single components or with a combined MMR + Chickenpox-vaccine of a high potency.